MBD1 Antibody

Overview

DNA methylation is the major modification of eukaryotic genomes and plays an essential role in mammalian development. Human proteins MECP2, MBD1, MBD2, MBD3, and MBD4 comprise a family of nuclear proteins related by the presence in each of a methyl-CpG binding domain (MBD). Each of these proteins, with the exception of MBD3, is capable of binding specifically to methylated DNA. MECP2, MBD1 and MBD2 can also repress transcription from methylated gene promoters. MBD1 has also been predicted to be involved in the development and progression of tumors, and it has been shown that MBD1 is significantly upregulated in pancreatic cancer tissues when compared with surrounding normal tissues. Furthermore, MBD1 may serve as a potential therapeutic target for pancreatic cancer.

This anti-MBD1 antibody is supplied as Purified (Mouse, Monoclonal (mouse origin), clone CPTC-MBD1-1, Mouse IgG1, kappa, Unconjugated) and is designed to support common target-detection workflows after the on-page specifications.

Key elements and design rationale

• Target: MBD1
• Format: Purified
• Localization: Nuclear
• Species reactivity: Human
• Applications (listed): IHC-P
• Conjugate: Unconjugated
• Clone and antibody class: Monoclonal (mouse origin), clone CPTC-MBD1-1, Mouse IgG1, kappa

Because antibody performance can depend on epitope context, sample preparation, and biological state, interpret signals using appropriate controls and orthogonal evidence when possible.

Biological background

MBD1 is referenced in public gene/protein resources (e.g., UniProt and NCBI Gene), which provide curated names/synonyms, protein features, and pathway context. When designing assays, consider potential isoforms, post-translational modifications, and cell-type specific expression that may influence observed signal.

Research relevance and current trends

• Profiling MBD1 expression across model systems, perturbations, and time points to support mechanistic hypotheses.
• Combining antibody-based detection with multi-omics or imaging readouts to link MBD1 signal with phenotype.
• Using well-matched controls (isotype controls, genetic perturbations, or independent reagents) to strengthen interpretation of target-associated signal.

Common research applications

• IHC-P

Use the listed applications as a starting point and tailor experimental design to your sample type and readout requirements.

Notes for experimental interpretation

• Specificity considerations: closely related family members, isoforms, or PTMs can affect apparent specificity; confirm with independent approaches when critical.
• Controls: include negative controls and, when feasible, genetic or pharmacologic perturbations to support target attribution in your system.
• Species and sample context: differences in sequence, expression, fixation, or extraction conditions can change signal behavior across models.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.